| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. | Chief Medical Officer | Class A Common Stock | 225,429 | $1,392,024 | $6.18 | 15 Nov 2024 | Direct |
| RECURSION PHARMACEUTICALS, INC. | Chief Medical Officer | Stock Option (Right to Buy) | 381,426 | 15 Nov 2024 | Direct | ||
| Codiak BioSciences, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 190,000 | 24 Jan 2023 | Direct | ||
| Prelude Therapeutics Inc | Chief Medical Officer | Employee Stock Option (Right to Buy) | 137,610 | 05 Oct 2021 | Direct | ||
| Codiak BioSciences, Inc. | Chief Medical Officer | Restricted Stock Units | 80,000 | 16 Sep 2022 | Direct | ||
| Prelude Therapeutics Inc | Chief Medical Officer | Common Stock | 0 | $3.77 | 05 Oct 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | 15 Nov 2024 | 1 | -$25,855 | 4 | Chief Medical Officer | 19 Nov 2024, 18:26 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 15 Aug 2024 | 1 | -$94,637 | 4 | Chief Medical Officer | 19 Aug 2024, 19:09 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 15 May 2024 | 1 | -$8,679 | 4 | Chief Medical Officer | 17 May 2024, 19:12 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 09 Feb 2024 | 4 | -$19,090 | 4 | Chief Medical Officer | 13 Feb 2024, 19:03 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 01 Jun 2023 | 2 | $0 | 4 | Chief Medical Officer | 07 Jun 2023, 19:36 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 01 Jun 2023 | 0 | $0 | 3 | Chief Medical Officer | 07 Jun 2023, 19:35 |
| /report/000089924323002758-mauro-david-j-2023-01-24 | Codiak BioSciences, Inc. | 24 Jan 2023 | 1 | $0 | 4 | Chief Medical Officer | 26 Jan 2023, 15:15 |
| /report/000089924322031587-mauro-david-j-2022-09-16 | Codiak BioSciences, Inc. | 16 Sep 2022 | 1 | $0 | 4 | Chief Medical Officer | 20 Sep 2022, 16:15 |
| /report/000089924322016604-mauro-david-j-2022-05-02 | Codiak BioSciences, Inc. | 02 May 2022 | 2 | $0 | 4 | Chief Medical Officer | 04 May 2022, 16:29 |
| /report/000089924322016602-mauro-david-j-2022-05-02 | Codiak BioSciences, Inc. | 02 May 2022 | 0 | $0 | 3 | Chief Medical Officer | 04 May 2022, 16:25 |
| PRLD | Prelude Therapeutics Inc | 05 Oct 2021 | 5 | -$436,000 | 4 | Chief Medical Officer | 06 Oct 2021, 18:02 |
| PRLD | Prelude Therapeutics Inc | 07 Sep 2021 | 5 | -$521,933 | 4 | Chief Medical Officer | 09 Sep 2021, 16:53 |
| PRLD | Prelude Therapeutics Inc | 05 Aug 2021 | 6 | -$438,044 | 4 | Chief Medical Officer | 09 Aug 2021, 16:26 |
| PRLD | Prelude Therapeutics Inc | 20 Jul 2021 | 1 | $0 | 4 | Chief Medical Officer | 22 Jul 2021, 18:13 |
| PRLD | Prelude Therapeutics Inc | 06 Jul 2021 | 5 | -$383,757 | 4 | Chief Medical Officer | 08 Jul 2021, 17:41 |
| PRLD | Prelude Therapeutics Inc | 07 Jun 2021 | 5 | -$458,272 | 4 | Chief Medical Officer | 09 Jun 2021, 18:24 |
| PRLD | Prelude Therapeutics Inc | 05 May 2021 | 5 | -$573,742 | 4 | Chief Medical Officer | 10 May 2021, 16:37 |